Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance of BRAFV600E-mutant melanoma to Vemurafenib: a senescence-induced swing from differentiation to blastulation followed by proliferation.

Cancer letters - 28 May 2026

Rumnieks Felikss, Vainshelbaum Ninel M, Salmina Kristine, Lazovska Maria, Kreismane Madara, Pjanova Dace, Zalums Justs, Vaivode Kristine, Saliba Daniel Ross, Zayakin Pawel, Freivalds Talivaldis, Perminov Dmitry, Kasperski Andrzej, Scherthan Harry, Cragg Mark Steven, Erenpreisa Jekaterina

Abstract excerpt

Resistance to Vemurafenib (VEM), a targeted BRAFV600E inhibitor, was examined in the metastatic paratetraploid (XX, abnormal Y chromosome) melanoma cell line, SkMel28. During the first week of treatment, pERK suppression coincided with transcriptomic and phenotypic changes related to senescence, autophagy/mitophagy, neuro-melanogenesis, and cell co-alignment. By the second week, MAPK-ERK signalling was restored,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Senescence
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanins

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 41831518
DOI: 10.1016/j.canlet.2026.218430

Genes

FOS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance of BRAFV600E-mutant melanoma to Vemurafenib: a senescence-induced swing from differentiation to blastulation followed by proliferation.PMID 41831518Read ↗

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.Semantic proximity Read ↗

Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulationsSemantic proximity Read ↗

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanomaSemantic proximity Read ↗

Melanomagenesis: Overcoming the barrier of melanocyte senescenceSemantic proximity Read ↗

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation ProgramSemantic proximity Read ↗

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblastsSemantic proximity Read ↗

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanomaSemantic proximity Read ↗

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR ExpressionSemantic proximity Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

The Convergence of Senescence and Ferroptosis Amplifies DNA Damage and Triggers Apoptosis in Patient-Derived Melanoma ModelsSemantic proximity Read ↗

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.Semantic proximity Read ↗

Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.